Osimertinib was the first drug to be approved for adjuvant treatment after complete tumor resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC). In an early benefit assessment, the German Institute ...
Oct 1, 2021
0
5
The Phase III IMpower010 trial evaluating atezolizumab vs. best supportive care after surgical resection and adjuvant chemotherapy met its primary endpoint showing significant disease-free survival improvement for patients ...
Sep 9, 2021
0
0
(HealthDay)—One year of adjuvant olaparib should be offered to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant ...
Jul 9, 2021
0
2
Obese patients with colorectal cancer receive lower cumulative doses of adjuvant chemotherapy, relative to their body surface area (BSA), than non-obese patients, show results from a large meta-analysis reported at the ESMO ...
Jul 2, 2021
0
2
(HealthDay)—For patients with early breast cancer, five years of zoledronate treatment after chemotherapy does not improve prognosis versus two years of treatment, according to a study published online June 24 in JAMA Oncology.
Jun 25, 2021
0
2
A retrospective study conducted by scientists from the Comprehensive Cancer Center (CCC) of MedUni Vienna and Vienna General Hospital found that compiling a tumor molecular profile can result in better risk stratification ...
May 11, 2021
0
1
(HealthDay)—For patients with stage II pancreatic cancer, attempted surgery with margin-positive resection may offer survival benefit over chemotherapy alone, according to a study published online March 26 in the Journal ...
Apr 22, 2021
0
2
The first comprehensive, prospective study of smoking habits in patients with non-small cell lung cancer (NSCLC) who were enrolled in a phase III early-stage trial revealed that there was a high rate of smoking reduction ...
Feb 1, 2021
0
5
A phase III study examining whether messenger (m)RNA expression correlated with sensitivity or resistance to chemotherapy did not confer a statistically significant advantage in overall survival for patients with resected ...
Jan 30, 2021
0
0
Post-operative radiotherapy (PORT) used in patients with non-small-cell lung cancer (NSCLC) following complete resection and after (neo) adjuvant chemotherapy shows no statistically significant difference in 3-year disease-free ...
Sep 20, 2020
0
3
